

subject of active research. The problem is that the simplest form of supersymmetry, with the most natural assumptions, predicts too large an electric dipole moment for the neutron. The simplest way to improve that situation leads to the opposite extreme, where the predicted electric dipole moments are much too small to measure. In-between situations are possible, but no one has yet proved that they are implied by the supersymmetry theory.

Thus a positive experimental result would have major implications because it would tell us some properties of the basic theory, and a negative result would help almost as much by telling us the theory does not have those properties. The results of these "low-budget" experiments would complement the Superconducting Super Collider (SSC) physics. The SSC will detect or exclude most of the new particles predicted by supersymmetry, including the light Higgs boson, and thus arrive at definite conclusions about whether supersymmetry is indeed the next stage of understanding of particles and their interactions. Eventually data from the SSC and other colliders can lead to a basic theoretical description if nature is supersymmetric; but one of the most difficult tasks for the SSC would be getting data on the relative phases of various parts of the basic theory, and it is just these phases to which the complementary information from the electric dipole moment experiments is most sensitive.

Gordon L. Kane  
Department of Physics,  
University of Michigan,  
Ann Arbor, MI 48109-1120

### Corrections and Clarifications

In the report "Secondary and tertiary structural effects on protein NMR chemical shifts: An ab initio approach" by Angel C. de Dios *et al.* (4 June, p. 1491), the abscissas of figure 1, B and D, on page 1492 were inadvertently transposed during production. Figure 1B's abscissa should have read, "Cutoff radius (Å)," and figure 1D's abscissa should have read, "Experiment (ppm)."

In John Travis' article "Novel anticancer agents move closer to reality" (Research News, 25 June, p. 1877), work by investigators at the Eisai Research Institute in Andover, Massachusetts, is mentioned. This work will appear in a forthcoming issue of the *Journal of Biological Chemistry*, not the *Journal of Biochemistry*, as implied.

Explanatory material was omitted from the bar graph accompanying the article "World Bank report calls for network to bolster research" by Peter Aldhous (News & Comment, 9 July, p. 155). The y axis should have been labeled "Disability-adjusted life years per 1000 population."

# IL-2R

## T Cell Diagnostics takes soluble IL-2R testing to its Maximum!

performance

T Cell Diagnostics, Inc. brings to you the most sophisticated IL-2R Test Kit available today. With unparalleled performance, the Cellfree® IL-2R EIA Test Kit is the one most used by researchers. And now it's better than ever.


flexibility

responsiveness

For more information or to order, call:  
(800) 624-4021 or  
(617) 621-1410.  
In Europe  
(44) 0865-873489

convenience

sensitivity



HELPING YOU EXPLORE THE IMMUNE RESPONSE

T Cell Diagnostics, 38 Sidney St., Cambridge, MA 02139

T Cell Diagnostics Europe, 28 Crown Road, Wheatley, Oxford OX33 1UL, U.K.

T CELL DIAGNOSTICS

Representative Office: Northrup Biotechnology, Inc., 100 S. Palm Ave., Suite 100, Palm Beach Gardens, FL 33460

Circle No. 33 on Readers' Service Card

### BIOTECH Patent News

On the Horizon . . .

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

BIOTECH Patent News

United States Patents

Catch, Carcinoma (Emeryville, CA) has applied for a covering therapeutic methods utilizing catalytic patent.

## WHAT'S THE LATEST NEWS ABOUT PATENTED BIOTECHNOLOGY?

Understanding the patent news of biotechnology is essential to understanding the business news of biotechnology.

You need to know what biotechnology is being patented. You need to know what biotechnology is being examined by the United States and European Patent Offices. And you need to know how government actions, biotechnology litigations, and research collaborations are affecting patent positions of various companies.

A subscription to **BIOTECH Patent News** can help you make informed decisions about your research and product development strategies.

Let **BIOTECH Patent News** give you an advantage! Twelve monthly issues of important, concise biotechnology patent news cost just \$95.00.

BIOTECH Patent News  
PO Box 4482  
Metuchen, NJ 08840  
(908) 549-1356

Name \_\_\_\_\_  
Company \_\_\_\_\_  
Street \_\_\_\_\_  
City/State/Zip \_\_\_\_\_

☐ Send me a FREE issue  
☐ Enclosed is a check for \$95 payable to BIOTECH Patent News.  
☐ Please bill me for one year of BIOTECH Patent News.  
Name: \_\_\_\_\_ Title: \_\_\_\_\_

Telephone 908-549-1356 TODAY for your FREE issue of **BIOTECH Patent News** or fill out and mail the coupon. **YOU'LL BE GLAD YOU DID.**

Circle No. 31 on Readers' Service Card